Status:
COMPLETED
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
Lead Sponsor:
Pfizer
Conditions:
Huntington's Disease
Eligibility:
All Genders
30-65 years
Phase:
PHASE2
Brief Summary
This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Hunting...
Eligibility Criteria
Inclusion
- CAG repeat equal or greater than 36;
- Total motor score equal or greater than 10;
- Total functional capacity equal or greater than 7.
Exclusion
- Clinically significant neurologic disorder other than Huntington's disease;
- Other severe acute psychiatric conditions, mania and/or psychosis;
- History of neutropenia, and myeloproliferative disorders;
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2016
Estimated Enrollment :
272 Patients enrolled
Trial Details
Trial ID
NCT02197130
Start Date
September 1 2014
End Date
October 1 2016
Last Update
November 17 2017
Active Locations (57)
Enter a location and click search to find clinical trials sorted by distance.
1
The Kirklin Clinic of UAB Hospital
Birmingham, Alabama, United States, 35233
2
The University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
3
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
4
Mayo Clinic Arizona
Phoenix, Arizona, United States, 85054